FridayOct 30, 2026 10:00 am

Dual-Impact Antibody Combats Multiple Tumor Types in Preclinical Study

Immunotherapy is a relatively new approach in the treatment of cancer and it has had profound effects on the patients who are responsive to these treatments. Researchers have been working to find ways of making the therapy effective for more categories of patients, since the current immunotherapies don’t work for everyone.  Now a new study has found a way to make these treatments more effective by targeting more than one protein in the tumor microenvironment. The effect of this dual-targeting approach was that the antibody used managed to suppress a variety of tumor types in mice. The cancer types included…

Continue Reading

ThursdayOct 29, 2026 10:30 am

Oncotelic Advances PLA from Published Liver Cancer Findings Toward 100 Billion Protein Vectors

PLA gives overlooked biological evidence its own analysis before combining the findings. Published HCC research connects PLA-guided investigation with a four-gene survival signature validated in an independent patient cohort. As Anthropic and OpenAI expand biological discovery with AI agents, Oncotelic is targeting a 100-billion-vector protein program. Oncotelic Therapeutics Inc. (OTCQB: OTLC) is building its PDAOAI drug discovery engine around a compelling premise: a clue buried in a small corner of the literature can redirect an entire research program. Its Partitioned Literature Aggregation (“PLA”) algorithm is designed to uncover those clues. A liver-cancer study published in Biomedicines on October 23, 2026,…

Continue Reading

ThursdayOct 29, 2026 10:00 am

Universal Healthcare Could Be a Key Issue During the Midterms

Abdul El-Sayed, a Democrat vying to win a U.S. Senate seat in Michigan, has become a nationally renowned figure after he built his campaign around advocating for a single payer healthcare system, popularly known as Medicare for all. During a recent campaign tour, he was accompanied by Democratic firebrand Alexandria Ocasio-Cortez (AOC). The animated crowds that attended all their rallies pose the question, is universal healthcare going to be a deciding factor as to who wins different races during the midterms next week? It isn’t easy to say, because there are many nuances to the issue. For starters, universal healthcare…

Continue Reading

TuesdayOct 27, 2026 10:00 am

Mutated Flu Version is Spreading on the West Coast

Many people have been taken by surprise as the flu season gets underway a lot earlier than had been expected in the U.S. The driver of this outbreak, especially on the West Coast, is a mutated flu version. Experts are calling for urgent vaccination drives to safeguard more people against this new threat.  Doctor Alex Greninger, The University of Washington’s Infectious Diseases Diagnostics chief, says flu outbreaks have been recorded on the West Coast before regions that usually experience flu season first. This is unusual, and has experts alarmed.  The season has started nearly three months earlier than is typically…

Continue Reading

FridayOct 23, 2026 10:10 am

Peter Thiel, OpenAI Back Brain Implant Firm Targeting Cancer

Coherence Neuro, a startup making implants designed to fight brain cancer, recently raised $45 million in a Series A funding round. The round was co-led by Peter Thiel’s Founders Fund and the OpenAI Startup Fund. Other notable participants included Lux Capital, Olive Capital and 8VC.  In a post, Coherence explained that the funds collected would enable the firm to conduct their first chronic human trial to test their implant as a treatment option for glioblastoma. The firm will also seek FDA designation of the implant as a breakthrough device. The company added that they would expand their tests to other…

Continue Reading

FridayOct 23, 2026 9:00 am

Why Adaptogenics Health Corp. (CSE: ADPT) Is ‘One to Watch’

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertisements. Adaptogenics is pursuing three complementary opportunities across pharmaceutical-quality peptide supply, proprietary therapeutics and next-generation delivery technologies. Its planned supply network could generate commercial revenue while supporting therapeutic development through external manufacturing and laboratory partners. The company is targeting metabolic health, muscle preservation, mitochondrial function, recovery and healthy ageing through proprietary peptide and small-molecule therapeutics. CEO Dr. J. David Warren brings a scientific record that includes 17 issued patents, while President Antoun Nabhan brings experience spanning more than $2 billion in healthcare transactions and two Nasdaq IPO processes. Adaptogenics…

Continue Reading

ThursdayOct 22, 2026 10:00 am

Researchers Discover That Brain Cancers Mutate Differently When Exposed to Treatment

Researchers at Yale School of Medicine have found that as brain cancers become more resistant to treatment, they develop a variety of mutations that differ from one type of brain cancer to another. This study could pave the way for developing more targeted treatments and allowing clinicians to switch from one-size-fits-all approaches to more personalized therapies.  The researchers focused on oligodendrogliomas and astrocytomas, common types of gliomas that afflict humans. The team found that as these sub-categories of brain cancer become more aggressive, they develop mutations that are radically different.  For a long time, scientists have worked based on the…

Continue Reading

ThursdayOct 22, 2026 9:45 am

Durability as the New Standard in Cartilage Repair: Why Long-Term Results Are Reshaping Global Orthopedics

Orthopedic care is increasingly focused not only on relieving symptoms, but on delivering durable outcomes that can stand up over time. That shift is creating greater interest in regenerative approaches designed to restore damaged tissue rather than simply address the immediate effects of injury. Regentis Biomaterials is advancing this approach with GelrinC, a degradable hydrogel implant designed to support the regeneration of durable cartilage in the knee. Orthopedic medicine has long focused on relieving pain and restoring mobility. Increasingly, though, the question is: How well will the result hold up over time? That question is particularly important in cartilage repair.…

Continue Reading

ThursdayOct 22, 2026 9:00 am

Nano-X Imaging Ltd. (NASDAQ: NNOX) Advances Its Mission to Expand Access to Medical Imaging

Nanox is working to make advanced medical imaging more accessible through digital 3D tomosynthesis technology designed to enhance visualization beyond conventional X-rays. Its Nanox.ARC platform combines imaging hardware with cloud-based infrastructure, while the company’s broader services support image interpretation and clinical workflows. By connecting image acquisition with remote radiology expertise and AI-powered analysis, Nanox aims to support healthcare providers’ imaging and interpretation workflows more efficiently. Access to medical imaging remains an important consideration for healthcare systems, particularly in underserved regions where equipment, infrastructure and trained personnel may be limited. While conventional X-rays play an essential role in diagnostic care, their…

Continue Reading

TuesdayOct 20, 2026 10:00 am

Bangladesh’s Measles Outbreak Provides Global Cautionary Tale

Bangladesh is currently grappling with a major measles outbreak that has seen more than 200,000 suspected cases of the disease recorded in the country, so far. Of those suspected cases, 22,000 have been confirmed by laboratory tests. These statistics cover mid-March to early October, according to the World Health Organization.  WHO says 1,147 fatalities due to the disease have so far been recorded in the country, and 94% of those reported deaths are of kids aged five years or less.  The Bangladesh situation underscores how challenging it can be to contain a measles outbreak at a time when vaccination uptake…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000